Treatment of Catastrophic Antiphospholipid Syndrome with Pulmonary Embolism
In patients with catastrophic antiphospholipid syndrome (CAPS) presenting with pulmonary embolism, initiate immediate triple therapy consisting of: (1) therapeutic anticoagulation with a vitamin K antagonist (VKA), NOT a DOAC, (2) high-dose glucocorticoids, and (3) plasma exchange and/or intravenous immunoglobulins.
Anticoagulation: VKA is Mandatory
The 2026 AHA/ACC/ACCP guidelines provide Class 1, Level A evidence that in patients with acute PE and established thrombotic antiphospholipid antibody syndrome, a VKA is recommended in preference to a DOAC for the prevention of venous and arterial thrombosis 1. This is critical because DOACs have been associated with treatment failure and recurrent thrombosis in APS patients 2, 3.
- Start therapeutic anticoagulation immediately—this is the only intervention with proven mortality benefit in CAPS 4
- Use warfarin or another VKA, targeting INR 2-3 (or 3-4 in refractory cases)
- Never use DOACs in established APS—a recent case demonstrated catastrophic consequences when a patient was switched from warfarin to rivaroxaban, resulting in life-threatening recurrent thrombosis and pulmonary hypertension 3
- If parenteral anticoagulation is needed initially (e.g., hemodynamic instability), use LMWH or UFH, then bridge to VKA 1
Immunomodulatory Triple Therapy
CAPS requires aggressive immunosuppression beyond anticoagulation alone. The standard approach combines 5, 4:
High-Dose Glucocorticoids
- Pulse methylprednisolone (500-1000 mg IV daily for 3-5 days) followed by oral prednisone 1 mg/kg/day
- Addresses the cytokine storm and thrombotic microangiopathy underlying CAPS 5
Plasma Exchange and/or IVIG
- Plasma exchange removes pathogenic antiphospholipid antibodies
- IVIG (0.4 g/kg/day for 5 days) neutralizes circulating antibodies
- Use one or both depending on severity and availability 6, 7, 4
Escalation for Refractory Disease
If thrombosis progresses despite triple therapy:
Rituximab
- 375 mg/m² weekly for 4 weeks, or 1000 mg on days 1 and 15
- Depletes CD20+ B cells, reducing pathogenic antibody production
- Multiple recent cases demonstrate efficacy in refractory CAPS 6, 7, 4
Eculizumab
- Consider in severe, life-threatening cases
- Inhibits complement C5, blocking C5b-C9 complex formation
- Emerging evidence supports use in refractory CAPS 4
Critical Management Considerations
Bleeding vs. Thrombosis Paradox: CAPS patients may have thrombocytopenia and bleeding risk alongside thrombosis 6, 8. Do not withhold anticoagulation based on platelet count alone—the thrombotic risk far exceeds bleeding risk in CAPS. One case demonstrated successful management despite concurrent intramuscular hemorrhage and thrombocytopenia 6.
Identify and Treat Triggers: CAPS is often precipitated by infection, surgery, or medication changes 5, 7. The case series shows infections (UTI) triggering fulminant multi-organ thrombosis 6. Screen for and aggressively treat any infectious trigger.
Multi-Organ Monitoring: CAPS involves rapid progression affecting kidneys, brain, heart, lungs, spleen, adrenals, and retina 6, 7. Monitor for:
- Renal failure (thrombotic microangiopathy)
- Adrenal insufficiency (bilateral adrenal thrombosis)
- Neurologic changes (cerebral thrombosis)
- Cardiac involvement (intracardiac thrombus extension) 7
Differential Diagnosis Pitfalls
CAPS mimics disseminated intravascular coagulation (DIC), heparin-induced thrombocytopenia (HIT), and other thrombotic microangiopathies 8. Key distinguishing features:
- Positive lupus anticoagulant and anticardiolipin/anti-β2-glycoprotein I antibodies (confirm at 12 weeks) 6, 8
- Normal or prolonged APTT (not shortened as in DIC)
- Thrombocytopenia with thrombosis (not just bleeding)
The mortality rate in CAPS remains 30-50% despite treatment, making early recognition and aggressive intervention absolutely essential 5, 4.